Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 4/20 | 0.47 |
| ▸ | PRKCZ known ✓ | Q05513 | 3/20 | 0.40 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.40 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.64 |
| ▸ | CNR2 | P34972 | 5/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748630 | 0.99 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL1748594 | 0.99 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL31589469 | 0.99 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL1748655 | 0.99 | CNR1 (0.65) | CNR1CNR2PDE5ANR3C2KIF11 | |
| Hydrochloric Acid SCHEMBL2020887 | 0.93 | CNR1 (0.57) | CNR1CNR2PDE5ANR3C2KIF11 | |
| Hydrochloric Acid SCHEMBL2021048 | 0.93 | CNR1 (0.57) | CNR1CNR2PDE5ANR3C2 | |
| SCHEMBL2015856 | 0.93 | CNR1 (0.59) | CNR1CNR2PDE5ANR3C2PRKCZ | |
| SCHEMBL2021231 | 0.93 | CNR1 (0.59) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL14395009 | 0.92 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2KIF11 | |
| SCHEMBL2017880 | 0.92 | CNR1 (0.58) | CNR1CNR2PDE5ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626963-B1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1910299-B1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7998996-B2 | Controlling triglyceride concentration; central nervous system disorders; psychological disorders; eating disordes; drug abuse; anticancer agents | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-08-16 | — | — | US | disclosed |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-7968582-B2 | 5(S)-substituted pyrazoline compounds, their preparation and use as medicaments | LABOROTORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-28 | — | — | US | disclosed |
| US-7897589-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-01 | — | — | US | disclosed |
| US-20090149472-A1 | SALTS OF SUBSTITUTTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AND MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-11 | — | — | US | disclosed |
| US-7524868-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-28 | — | — | US | disclosed |
| US-20080207637-A1 | Substituted Pyrazoline Compounds for Reducing Triglycerides in Blood | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-28 | — | — | US | disclosed |
| EP-1743638-A1 | Pharmaceutical formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743888-A1 | Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1718619-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | disclosed |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| EP-1637522-A1 | Substituted pyrazoline compounds for reducing triglycerides in blood | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-22 | — | — | EP | disclosed |
| EP-1626963-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | disclosed |
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| WO-2005077911-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077909-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | PDE5A 535/4885PRKCZ 1503/4885GABRA2 2061/4885 |
| US-20090149472-A1 | SALTS OF SUBSTITUTTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AND MEDICAMENTS | SYMPK, SLC35B2, PNPO | PDE5A 470/4885PRKCZ 1328/4885GABRA2 1287/4885 |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | PDE5A 535/4885PRKCZ 1503/4885GABRA2 2061/4885 |
| US-20080207637-A1 | Substituted Pyrazoline Compounds for Reducing Triglycerides in Blood | APOB, PNLIP, LIPC | PDE5A 386/4885PRKCZ 1081/4885GABRA2 4012/4885 |
| US-20110160181-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIR, SYMPK, P2RX5 | PDE5A 535/4885PRKCZ 1503/4885GABRA2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.